Experts Compare Available Regimens for a Patient With Sarcomatoid FeaturesMarch 2nd 2021
During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to DingliFebruary 26th 2021
David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, reviews the combination therapies available for the treatment of multiple myeloma in a patient who is 72-years-old and transplant-ineligible.
Historical and Current Data Inform the Ovarian Treatment Landscape for Practicing OncologistsFebruary 21st 2021
Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.
Park Discusses Targeted Therapy Trials in Intermediate- and High-Risk ccRCCFebruary 21st 2021
In a 7 to 1 vote, oncologists favored the use of axitinib in combination with pembrolizumab or avelumab over cabozantinib monotherapy for the treatment of intermediate and high-risk clear cell renal cell carcinoma. Chandler H. Park, MD, reviewed that clinical trial research that supports the axitinib combinations, as well as other targeted therapy options.
Bekaii-Saab Explores Chemotherapies and Targeted Treatment Options in Metastatic CRCFebruary 3rd 2021
During a virtual Targeted Oncology Case-Based Peer Perspectives event, Dr. Tanios Bekaii-Saab discussed the chemotherapy and targeted treatment options available for the treatment of patients with metastatic colorectal cancer with participating oncologists.